Published in Antimicrob Agents Chemother on September 12, 2011
The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. Clin Microbiol Rev (2015) 1.81
Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance. Clin Microbiol Rev (2012) 1.74
Alterations of OprD in carbapenem-intermediate and -susceptible strains of Pseudomonas aeruginosa isolated from patients with bacteremia in a Spanish multicenter study. Antimicrob Agents Chemother (2012) 1.13
MexXY multidrug efflux system of Pseudomonas aeruginosa. Front Microbiol (2012) 1.11
LpxC inhibitors as new antibacterial agents and tools for studying regulation of lipid A biosynthesis in Gram-negative pathogens. MBio (2014) 0.95
Multiple mutations lead to MexXY-OprM-dependent aminoglycoside resistance in clinical strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother (2013) 0.94
MexT functions as a redox-responsive regulator modulating disulfide stress resistance in Pseudomonas aeruginosa. J Bacteriol (2012) 0.86
Efflux-mediated fluoroquinolone resistance in the multidrug-resistant Pseudomonas aeruginosa clinical isolate PA7: identification of a novel MexS variant involved in upregulation of the mexEF-oprN multidrug efflux operon. Front Microbiol (2015) 0.82
Emergence of the P2 phenotype in Pseudomonas aeruginosa PAO1 strains involves various mutations in mexT or mexF. J Bacteriol (2013) 0.80
Amino Acid Substitutions Account for Most MexS Alterations in Clinical nfxC Mutants of Pseudomonas aeruginosa. Antimicrob Agents Chemother (2016) 0.78
Pseudomonas aeruginosa Lifestyle: A Paradigm for Adaptation, Survival, and Persistence. Front Cell Infect Microbiol (2017) 0.76
The role of gyrA and parC mutations in fluoroquinolones-resistant Pseudomonas aeruginosa isolates from Iran. Braz J Microbiol (2016) 0.75
Molecular epidemiology of mutations in antimicrobial resistance loci of Pseudomonas aeruginosa isolates from cystic fibrosis airways. Antimicrob Agents Chemother (2016) 0.75
Production of single-stranded plasmid DNA. Methods Enzymol (1987) 39.38
Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature (2000) 32.30
Improved broad-host-range plasmids for DNA cloning in gram-negative bacteria. Gene (1988) 18.10
Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa. Mol Microbiol (1997) 5.91
Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev (2009) 5.76
Gyrase inhibitors induce an oxidative damage cellular death pathway in Escherichia coli. Mol Syst Biol (2007) 3.98
Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother (2000) 3.78
New norfloxacin resistance gene in Pseudomonas aeruginosa PAO. Antimicrob Agents Chemother (1990) 3.71
Multiplex PCR for detection of plasmid-mediated quinolone resistance qnr genes in ESBL-producing enterobacterial isolates. J Antimicrob Chemother (2007) 3.61
Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria. Antimicrob Agents Chemother (2000) 3.22
Quinolone-mediated bacterial death. Antimicrob Agents Chemother (2007) 2.94
Population structure of Pseudomonas aeruginosa. Proc Natl Acad Sci U S A (2007) 2.56
Global GacA-steered control of cyanide and exoprotease production in Pseudomonas fluorescens involves specific ribosome binding sites. Proc Natl Acad Sci U S A (1999) 2.37
Advancing the quorum in Pseudomonas aeruginosa: MvaT and the regulation of N-acylhomoserine lactone production and virulence gene expression. J Bacteriol (2002) 2.34
Overexpression of the MexEF-OprN multidrug efflux system affects cell-to-cell signaling in Pseudomonas aeruginosa. J Bacteriol (2001) 2.28
Clinical strains of Pseudomonas aeruginosa overproducing MexAB-OprM and MexXY efflux pumps simultaneously. Antimicrob Agents Chemother (2004) 2.26
Analysis of antibiotic resistance gene expression in Pseudomonas aeruginosa by quantitative real-time-PCR. FEMS Microbiol Lett (2006) 2.10
Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother (2000) 2.07
Differential selection of multidrug efflux systems by quinolones in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1997) 2.06
Characterization of MexT, the regulator of the MexE-MexF-OprN multidrug efflux system of Pseudomonas aeruginosa. J Bacteriol (1999) 1.96
OprK and OprM define two genetically distinct multidrug efflux systems in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1995) 1.83
Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance. Antimicrob Agents Chemother (2001) 1.77
Involvement of the MexXY-OprM efflux system in emergence of cefepime resistance in clinical strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother (2006) 1.75
Resistance mechanisms of multiresistant Pseudomonas aeruginosa strains from Germany and correlation with hypermutation. Antimicrob Agents Chemother (2007) 1.63
Variation of the mexT gene, a regulator of the MexEF-oprN efflux pump expression in wild-type strains of Pseudomonas aeruginosa. FEMS Microbiol Lett (2000) 1.60
Role of efflux pumps and mutations in genes for topoisomerases II and IV in fluoroquinolone-resistant Pseudomonas aeruginosa strains. Microb Drug Resist (2003) 1.58
Role of the multidrug efflux system MexXY in the emergence of moderate resistance to aminoglycosides among Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother (2004) 1.57
Induction of the MexXY efflux pump in Pseudomonas aeruginosa is dependent on drug-ribosome interaction. J Bacteriol (2005) 1.55
Type II topoisomerase mutations in ciprofloxacin-resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1999) 1.55
Low-level antibacterial resistance: a gateway to clinical resistance. Drug Resist Updat (2001) 1.52
Genetic and phenotypic variations of a resistant Pseudomonas aeruginosa epidemic clone. Antimicrob Agents Chemother (2003) 1.48
An H(+)-coupled multidrug efflux pump, PmpM, a member of the MATE family of transporters, from Pseudomonas aeruginosa. J Bacteriol (2004) 1.42
Analysis of acquired ciprofloxacin resistance in a clinical strain of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1990) 1.40
Mutation in the DNA gyrase A Gene of Escherichia coli that expands the quinolone resistance-determining region. Antimicrob Agents Chemother (2001) 1.40
Enhancement of the mexAB-oprM efflux pump expression by a quorum-sensing autoinducer and its cancellation by a regulator, MexT, of the mexEF-oprN efflux pump operon in Pseudomonas aeruginosa. Antimicrob Agents Chemother (2004) 1.40
Adaptive mutations produce resistance to ciprofloxacin. Antimicrob Agents Chemother (1997) 1.37
Global regulation of quorum sensing and virulence by VqsR in Pseudomonas aeruginosa. Microbiology (2004) 1.32
A new member of the tripartite multidrug efflux pumps, MexVW-OprM, in Pseudomonas aeruginosa. J Antimicrob Chemother (2003) 1.29
Mutations in PA2491 (mexS) promote MexT-dependent mexEF-oprN expression and multidrug resistance in a clinical strain of Pseudomonas aeruginosa. J Bacteriol (2005) 1.29
Transcriptome analysis of Pseudomonas aeruginosa after interaction with human airway epithelial cells. Infect Immun (2004) 1.29
CzcR-CzcS, a two-component system involved in heavy metal and carbapenem resistance in Pseudomonas aeruginosa. J Biol Chem (2003) 1.27
Two efflux systems expressed simultaneously in multidrug-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother (2000) 1.18
Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. Antimicrob Agents Chemother (2008) 1.15
mexEF-oprN multidrug efflux operon of Pseudomonas aeruginosa: regulation by the MexT activator in response to nitrosative stress and chloramphenicol. Antimicrob Agents Chemother (2010) 1.12
Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother (2009) 1.07
MexAB-OprM- and MexXY-overproducing mutants are very prevalent among clinical strains of Pseudomonas aeruginosa with reduced susceptibility to ticarcillin. Antimicrob Agents Chemother (2007) 1.07
Functional cloning and characterization of a multidrug efflux pump, mexHI-opmD, from a Pseudomonas aeruginosa mutant. Antimicrob Agents Chemother (2003) 1.05
mvaT mutation modifies the expression of the Pseudomonas aeruginosa multidrug efflux operon mexEF-oprN. FEMS Microbiol Lett (2006) 1.03
MexT modulates virulence determinants in Pseudomonas aeruginosa independent of the MexEF-OprN efflux pump. Microb Pathog (2009) 1.00
Gene cloning and properties of the RND-type multidrug efflux pumps MexPQ-OpmE and MexMN-OprM from Pseudomonas aeruginosa. Microbiol Immunol (2005) 0.99
Bacteriostatic and bactericidal activities of eight fluoroquinolones against MexAB-OprM-overproducing clinical strains of Pseudomonas aeruginosa. J Antimicrob Chemother (2005) 0.98
MexT regulates the type III secretion system through MexS and PtrC in Pseudomonas aeruginosa. J Bacteriol (2010) 0.97
Fluoroquinolone susceptibilities of efflux-mediated multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Burkholderia cepacia. J Antimicrob Chemother (2001) 0.96
Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa. Int J Antimicrob Agents (2006) 0.95
Pharmacodynamics of levofloxacin against Pseudomonas aeruginosa with reduced susceptibility due to different efflux pumps: do elevated MICs always predict reduced in vivo efficacy? Antimicrob Agents Chemother (2006) 0.93
Transcriptional regulation of the mexEF-oprN multidrug efflux pump operon by MexT and an unidentified repressor in nfxC-type mutant of Pseudomonas aeruginosa. FEMS Microbiol Lett (2010) 0.84
Inactivation of MuxABC-OpmB transporter system in Pseudomonas aeruginosa leads to increased ampicillin and carbenicillin resistance and decreased virulence. J Microbiol (2011) 0.79
Contribution of ParE mutation and efflux to ciprofloxacin resistance in Pseudomonas aeruginosa clinical isolates. J Chemother (2008) 0.79
[Recovery method of serotypable character in non serotypable pseudomonas aeruginosa strains]. Pathol Biol (Paris) (2004) 0.76
Population structure of Pseudomonas aeruginosa. Proc Natl Acad Sci U S A (2007) 2.56
Clinical strains of Pseudomonas aeruginosa overproducing MexAB-OprM and MexXY efflux pumps simultaneously. Antimicrob Agents Chemother (2004) 2.26
Analysis of antibiotic resistance gene expression in Pseudomonas aeruginosa by quantitative real-time-PCR. FEMS Microbiol Lett (2006) 2.10
Cooperation and virulence of clinical Pseudomonas aeruginosa populations. Proc Natl Acad Sci U S A (2009) 2.07
Pseudomonas aeruginosa virulence analyzed in a Dictyostelium discoideum host system. J Bacteriol (2002) 1.99
Involvement of the MexXY-OprM efflux system in emergence of cefepime resistance in clinical strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother (2006) 1.75
MexXY-OprM efflux pump is necessary for a adaptive resistance of Pseudomonas aeruginosa to aminoglycosides. Antimicrob Agents Chemother (2003) 1.58
Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. Antimicrob Agents Chemother (2007) 1.58
Role of the multidrug efflux system MexXY in the emergence of moderate resistance to aminoglycosides among Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother (2004) 1.57
Induction of the MexXY efflux pump in Pseudomonas aeruginosa is dependent on drug-ribosome interaction. J Bacteriol (2005) 1.55
Rhamnolipids are virulence factors that promote early infiltration of primary human airway epithelia by Pseudomonas aeruginosa. Infect Immun (2006) 1.52
Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients. Antimicrob Agents Chemother (2013) 1.49
Genetic and phenotypic variations of a resistant Pseudomonas aeruginosa epidemic clone. Antimicrob Agents Chemother (2003) 1.48
Characterization of cell-to-cell signaling-deficient Pseudomonas aeruginosa strains colonizing intubated patients. J Clin Microbiol (2004) 1.40
Quorum sensing inhibition selects for virulence and cooperation in Pseudomonas aeruginosa. PLoS Pathog (2010) 1.35
Biofilm formation by Pseudomonas aeruginosa: role of the C4-HSL cell-to-cell signal and inhibition by azithromycin. J Antimicrob Chemother (2003) 1.34
A two-component regulatory system interconnects resistance to polymyxins, aminoglycosides, fluoroquinolones, and β-lactams in Pseudomonas aeruginosa. Antimicrob Agents Chemother (2010) 1.28
Siderophores as drug delivery agents: application of the "Trojan Horse" strategy. Biometals (2009) 1.27
CzcR-CzcS, a two-component system involved in heavy metal and carbapenem resistance in Pseudomonas aeruginosa. J Biol Chem (2003) 1.27
Structure of Pseudomonas aeruginosa populations analyzed by single nucleotide polymorphism and pulsed-field gel electrophoresis genotyping. J Bacteriol (2004) 1.24
Pseudomonas aeruginosa virulence genes identified in a Dictyostelium host model. Cell Microbiol (2007) 1.24
Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France. Antimicrob Agents Chemother (2010) 1.24
Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. Antimicrob Agents Chemother (2006) 1.23
Azithromycin to prevent Pseudomonas aeruginosa ventilator-associated pneumonia by inhibition of quorum sensing: a randomized controlled trial. Intensive Care Med (2012) 1.22
Posttranscriptional control of quorum-sensing-dependent virulence genes by DksA in Pseudomonas aeruginosa. J Bacteriol (2003) 1.21
Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. Antimicrob Agents Chemother (2008) 1.15
DksA represses ribosomal gene transcription in Pseudomonas aeruginosa by interacting with RNA polymerase on ribosomal promoters. Mol Microbiol (2005) 1.14
Complexity of resistance mechanisms to imipenem in intensive care unit strains of Pseudomonas aeruginosa. J Antimicrob Chemother (2013) 1.14
Genotypic and phenotypic analysis of type III secretion system in a cohort of Pseudomonas aeruginosa bacteremia isolates: evidence for a possible association between O serotypes and exo genes. J Infect Dis (2003) 1.12
The Pseudomonas aeruginosa opportunistic pathogen and human infections. Environ Microbiol (2011) 1.11
Detection of Pseudomonas aeruginosa cell-to-cell signals in lung tissue of cystic fibrosis patients. Microb Pathog (2002) 1.11
Bacterial epidemiology and antimicrobial resistance in ascitic fluid: a 2-year retrospective study. Scand J Infect Dis (2009) 1.09
Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother (2009) 1.07
Lipopolysaccharide as shield and receptor for R-pyocin-mediated killing in Pseudomonas aeruginosa. J Bacteriol (2010) 1.07
MexAB-OprM- and MexXY-overproducing mutants are very prevalent among clinical strains of Pseudomonas aeruginosa with reduced susceptibility to ticarcillin. Antimicrob Agents Chemother (2007) 1.07
Quorum sensing-dependent virulence during Pseudomonas aeruginosa colonisation and pneumonia in mechanically ventilated patients. Thorax (2010) 1.06
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. Antimicrob Agents Chemother (2007) 1.06
Evidence for induction of integron-based antibiotic resistance by the SOS response in a clinical setting. PLoS Pathog (2012) 1.05
Overproduction of the multidrug efflux pump MexEF-OprN does not impair Pseudomonas aeruginosa fitness in competition tests, but produces specific changes in bacterial regulatory networks. Environ Microbiol (2012) 1.01
Detection of an IS21 insertion sequence in the mexR gene of Pseudomonas aeruginosa increasing beta-lactam resistance. FEMS Microbiol Lett (2004) 0.99
Bacteriostatic and bactericidal activities of eight fluoroquinolones against MexAB-OprM-overproducing clinical strains of Pseudomonas aeruginosa. J Antimicrob Chemother (2005) 0.98
Microbiological and epidemiological features of clinical respiratory isolates of Burkholderia gladioli. J Clin Microbiol (2009) 0.96
Diversity of β-lactam resistance mechanisms in cystic fibrosis isolates of Pseudomonas aeruginosa: a French multicentre study. J Antimicrob Chemother (2013) 0.95
Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother (2008) 0.95
Remission after treatment of osteoarticular infections due to Pseudomonas aeruginosa versus Staphylococcus aureus: a case-controlled study. Int Orthop (2011) 0.95
Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex. Antimicrob Agents Chemother (2008) 0.94
Multiple mutations lead to MexXY-OprM-dependent aminoglycoside resistance in clinical strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother (2013) 0.94
Evolving epidemiology and antimicrobial resistance in spontaneous bacterial peritonitis: a two-year observational study. BMC Infect Dis (2014) 0.92
Increased susceptibility of Pseudomonas aeruginosa to macrolides and ketolides in eukaryotic cell culture media and biological fluids due to decreased expression of oprM and increased outer-membrane permeability. Clin Infect Dis (2012) 0.92
Patterns and modes of beta-lactam resistance in Pseudomonas aeruginosa. Clin Microbiol Infect (1999) 0.92
Design and methodology of the Swiss Transplant Cohort Study (STCS): a comprehensive prospective nationwide long-term follow-up cohort. Eur J Epidemiol (2013) 0.91
Involvement of Fe uptake systems and AmpC β-lactamase in susceptibility to the siderophore monosulfactam BAL30072 in Pseudomonas aeruginosa. Antimicrob Agents Chemother (2013) 0.89
Strain-tailored double-disk synergy test detects extended-spectrum oxacillinases in Pseudomonas aeruginosa. J Clin Microbiol (2011) 0.88
Invasive zygomycosis in transplant recipients. Clin Transplant (2007) 0.88
Responses of solid organ transplant recipients to the AS03-adjuvanted pandemic influenza vaccine. Antivir Ther (2012) 0.87
Autoinducer production and quorum-sensing dependent phenotypes of Pseudomonas aeruginosa vary according to isolation site during colonization of intubated patients. BMC Microbiol (2007) 0.85
A convenient method to screen for carbapenemase-producing Pseudomonas aeruginosa. J Clin Microbiol (2013) 0.85
Detection of a new extended-spectrum oxacillinase in Pseudomonas aeruginosa. J Antimicrob Chemother (2009) 0.85
Ceftazidime-hydrolysing β-lactamase OXA-145 with impaired hydrolysis of penicillins in Pseudomonas aeruginosa. J Antimicrob Chemother (2011) 0.84
IMP-29, a novel IMP-type metallo-β-lactamase in Pseudomonas aeruginosa. Antimicrob Agents Chemother (2012) 0.84
Amino acid residues essential for function of the MexF efflux pump protein of Pseudomonas aeruginosa. Antimicrob Agents Chemother (2002) 0.84
Hospital outbreak of Pseudomonas aeruginosa producing extended-spectrum oxacillinase OXA-19. J Med Microbiol (2010) 0.83
Selection of an antibiotic-hypersusceptible mutant of Pseudomonas aeruginosa: identification of the GlmR transcriptional regulator. Antimicrob Agents Chemother (2004) 0.82
Human cysteine cathepsins are not reliable markers of infection by Pseudomonas aeruginosa in cystic fibrosis. PLoS One (2011) 0.81
Outcome of treated and untreated asymptomatic bacteriuria in renal transplant recipients. Nephrol Dial Transplant (2011) 0.81
Spread of the bla(IMP-13) gene in French Pseudomonas aeruginosa through sequence types ST621, ST308 and ST111. Int J Antimicrob Agents (2012) 0.81
Combining topology and sequence design for the discovery of potent antimicrobial peptide dendrimers against multidrug-resistant Pseudomonas aeruginosa. Angew Chem Int Ed Engl (2014) 0.80
TNFα blockade for inflammatory rheumatic diseases is associated with a significant gain in android fat mass and has varying effects on adipokines: a 2-year prospective study. Eur J Nutr (2013) 0.80
Unique biofilm signature, drug susceptibility and decreased virulence in Drosophila through the Pseudomonas aeruginosa two-component system PprAB. PLoS Pathog (2012) 0.80
Low incidence of severe respiratory syncytial virus infections in lung transplant recipients despite the absence of specific therapy. J Heart Lung Transplant (2009) 0.80
Pseudomonas aeruginosa-induced apoptosis in airway epithelial cells is mediated by gap junctional communication in a JNK-dependent manner. J Immunol (2014) 0.80
Cytomegalovirus serology and replication remain associated with solid organ graft rejection and graft loss in the era of prophylactic treatment. Transplantation (2014) 0.79
Outbreak of metallo-β-lactamase VIM-2-positive strains of Pseudomonas aeruginosa in the Ivory Coast. J Antimicrob Chemother (2013) 0.78
Role of MexAB-OprM in intrinsic resistance of Pseudomonas aeruginosa to temocillin and impact on the susceptibility of strains isolated from patients suffering from cystic fibrosis. J Antimicrob Chemother (2012) 0.77
Higher memory responses in HIV-infected and kidney transplanted patients than in healthy subjects following priming with the pandemic vaccine. PLoS One (2012) 0.77
[Urinary tract infections in adults]. Rev Med Suisse (2011) 0.77
Clonal dissemination of Pseudomonas aeruginosa isolates producing extended-spectrum β-lactamase SHV-2a. J Clin Microbiol (2012) 0.77
The swiss transplant cohort study: lessons from the first 6 years. Curr Infect Dis Rep (2015) 0.76
[Pseudomonas aeruginosa infections: from bench to bedside]. Rev Med Suisse (2009) 0.76
Herpes simplex virus load to monitor antiviral treatment after liver transplantation for acute herpetic hepatitis. Antivir Ther (2011) 0.76
Torque Teno Virus Load and Acute Rejection after Orthotopic Liver Transplantation. Transplantation (2017) 0.75
Protection From Varicella Zoster in Solid Organ Transplant Recipients Carrying Killer Cell Immunoglobulin-Like Receptor B Haplotypes. Transplantation (2015) 0.75
Lipidated Peptide Dendrimers Killing Multidrug Resistant Bacteria. J Am Chem Soc (2017) 0.75
Drug susceptibility testing by dilution methods. Methods Mol Biol (2014) 0.75